Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function Source: Eur Respir J 2012; 39: 279-289 Year: 2012
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Comparable efficacy of ciclesonide and fluticasone propionate and lower incidence of oropharyngeal candidiasis with ciclesonide in patients with well-controlled moderate to severe persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Reduction in oral corticosteroid use with mometasone furoate DPI improves health-related quality of life in patients with severe persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 395s Year: 2002
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007
Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003